Profile

Bayard L. Powell, M.D.Wake Forest Baptist Health

Doctor Rating

4.8 out of 5

162 Ratings
1 Comments

Bayard L. Powell, M.D.

Director-At-Large,
Section Chief,
Professor,

Clinical Interests

Acute Leukemias, Chronic Leukemias, Myelodysplastic Syndromes, Acute and Chronic Leukemia, Hematologic Malignancies, Leukemia

Contact Information

New Patient Appointments: 336-716-WAKE
Returning Patient Appointments: 336-713-5440
Department: 336-716-4464

Insurance Accepted »

Media Medical Expert »

Education & Training

  • B.S.E., Duke University , 1976
  • M.D., University of North Carolina School of Medicine , 1980
  • Residency, Internal Medicine, North Carolina Baptist Hospita, 1983
  • Fellowship, North Carolina Baptist Hospita, 1986

Board Certifications

  • American Board of Internal Medicine, Internal Medicine, Internal Medicine - Internal Medicine
  • American Board of Internal Medicine, Internal Medicine, Internal Medicine - Medical Oncology

Memberships

  • Am Coll Of Physicians
  • Am Soc Of Clinical Oncology
  • Am Soc Of Hematology
  • Assn Of Med Schl Professors Of
  • Cancer & Acute Leukemia Group

NPI Number

  • 1831173954
Bayard L. Powell, M.D.

Doctor Rating

4.8 out of 5

162 Ratings
1 Comments

Bayard L. Powell, M.D.

Director-At-Large, Comprehensive Cancer Center
Section Chief, Hematology & Oncology
Professor, Hematology & Oncology
Comprehensive Cancer Center

Research Interests

cancer/oncogenesis, drugs/therapeutic agents pharm

Contact Information

Academic: 336-716-7970 | Department: 336-716-4464

Media Medical Expert »

Recent Publications

Tawfik B, Sliesoraitis S, Lyerly S, Klepin HD, Lawrence J, Isom S, Ellis LR, Manuel M, Dralle S, Berenzon D, Powell BL, Pardee T. Efficacy of the hypomethylating agents as frontline, salvage, or consolidation therapy in adults with acute myeloid leukemia (AML). Ann Hematol. 2014;93(1):47-55.

Marcucci G, Yan P, Maharry K, Frankhouser D, Nicolet D, Metzeler KH, Kohlschmidt J, Mrozek K, Wu YZ, Bucci D, Curfman JP, Whitman SP, Eisfeld AK, Mendler JH, Schwind S, Becker H, Bar C, Carroll AJ, Baer MR, Wetzler M, Carter TH, Powell BL, Kolitz JE,. Epigenetics meets genetics in acute myeloid leukemia: clinical impact of a novel seven-gene score. J Clin Oncol. 2014;32(6):548-556.

Rizzieri DA, Johnson JL, Byrd JC, Lozanski G, Blum KA, Powell BL, Shea TC, Nattam S, Hoke E, Cheson BD, Larson RA. Improved efficacy using rituximab and brief duration, high intensity chemotherapy with filgrastim support for Burkitt or aggressive lymphomas: cancer and Leukemia Group B study 10 002. Br J Haematol. 2014;165(1):102-111.

Wetzler M, Watson D, Stock W, Koval G, Mulkey FA, Hoke EE, McCarty JM, Blum WG, Powell BL, Marcucci G, Bloomfield CD, Linker CA, Larson RA. Autologous transplantation for Philadelphia chromosome-positive acute lymphoblastic leukemia achieves outcomes similar to allogeneic transplantation: results of CALGB Study 10001 (Alliance). Haematologica. 2014;99(1):111-115.

Whitman SP, Kohlschmidt J, Maharry K, Volinia S, Mrozek K, Nicolet D, Schwind S, Becker H, Metzeler KH, Mendler JH, Eisfeld AK, Carroll AJ, Powell BL, Carter TH, Baer MR, Kolitz JE, Park IK, Stone RM, Caligiuri MA, Marcucci G, Bloomfield CD. GAS6 expression identifies high-risk adult AML patients: potential implications for therapy. Leukemia. 2014;28(6):1252-1258.

Coutre SE, Othus M, Powell B, Willman CL, Stock W, Paietta E, Levitan D, Wetzler M, Attar EC, Altman JK, Gore SD, Maher T, Kopecky KJ, Tallman MS, Larson RA, Appelbaum FR. Arsenic trioxide during consolidation for patients with previously untreated low/intermediate risk acute promyelocytic leukaemia may eliminate the need for maintenance therapy. Br J Haematol. 2014;165(4):497-503.

Kolitz JE, George SL, Benson DM Jr, Maharry K, Marcucci G, Vij R, Powell BL, Allen SL, Deangelo DJ, Shea TC, Stock W, Bakan CE, Hars V, Hoke E, Bloomfield CD, Caligiuri MA, Larson RA. Recombinant interleukin-2 in patients aged younger than 60 years with acute myeloid leukemia in first complete remission: results from Cancer and Leukemia Group B 19808. Cancer. 2014;120(7):1010-1017.

Becker H, Maharry K, Mrozek K, Volinia S, Eisfeld AK, Radmacher MD, Kohlschmidt J, Metzeler KH, Schwind S, Whitman SP, Mendler JH, Wu YZ, Nicolet D,. Prognostic gene mutations and distinct gene- and microRNA-expression signatures in acute myeloid leukemia with a sole trisomy 8 [letter]. Leukemia. 2014;28(8):1754-1758.

Poire X, Moser BK, Gallagher RE, Laumann K, Bloomfield CD, Powell BL, Koval G, Gulati K, Holowka N, Larson RA, Tallman MS, Appelbaum FR, Sher D, Willman C, Paietta E, Stock W. Arsenic trioxide in front-line therapy of acute promyelocytic leukemia (C9710): prognostic significance of FLT3 mutations and complex karyotype. Leuk Lymphoma. 2014;55(7):1523-1532.

Elliot K, Tooze JA, Geller R, Powell BL, Pardee TS, Ritchie E, Kennedy L, Callahan KE, Klepin HD. The prognostic importance of polypharmacy in older adults treated for acute myelogenous leukemia (AML). Leuk Res. 2014;38(10):1184-1190.

Niederwieser C, Kohlschmidt J, Volinia S, Whitman SP, Metzeler KH, Eisfeld AK, Maharry K, Yan P, Frankhouser D, Becker H, Schwind S, Carroll AJ, Nicolet D, Mendler JH, Curfman JP, Wu YZ, Baer MR, Powell BL, Kolitz JE, Moore JO, Carter TH, Bundschuh R,. Prognostic and biologic significance of DNMT3B expression in older patients with cytogenetically normal primary acute myeloid leukemia. Leukemia. 2014;():.

Pardee TS, Lee K, Luddy J, Maturo C, Rodriguez R, Isom S, Miller LD, Stadelman KM, Levitan D, Hurd D, Ellis LR, Harrelson R, Manuel M, Dralle S, Lyerly S, Powell BL. A phase I study of the first-in-class antimitochondrial metabolism agent, CPI-613, in patients with advanced hematologic malignancies. Clin Cancer Res. 2014;20(20):5255-5264.

Danhauer SC, Russell GB, Tedeschi RG, Jesse MT, Vishnevsky T, Daley K, Carroll S, Triplett KN, Calhoun LG, Cann A, Powell BL. A longitudinal investigation of posttraumatic growth in adult patients undergoing treatment for acute leukemia. J Clin Psychol Med Settings. 2013;20(1):13-24.

Stock W, Johnson JL, Stone RM, Kolitz JE, Powell BL, Wetzler M, Westervelt P, Marcucci G, DeAngelo DJ, Vardiman JW, McDonnell D, Mrozek K, Bloomfield CD, Larson RA. Dose intensification of daunorubicin and cytarabine during treatment of adult acute lymphoblastic leukemia: results of Cancer and Leukemia Group B Study 19802. Cancer. 2013;119(1):90-98.

Attar EC, Johnson JL, Amrein PC, Lozanski G, Wadleigh M, DeAngelo DJ, Kolitz JE, Powell BL, Voorhees P, Wang ES, Blum W, Stone RM, Marcucci G, Bloomfield CD, Moser B, Larson RA. Bortezomib added to daunorubicin and cytarabine during induction therapy and to intermediate-dose cytarabine for consolidation in patients with previously untreated acute myeloid leukemia age 60 to 75 years: CALGB (Alliance) study 10502. J Clin Oncol. 2013;31(7):923-929.

Powell BL. Acute promyelocytic leukemia: progress far and wide [comment]. Blood. 2013;121(11):1925-1926.

Klepin HD, Geiger AM, Tooze JA, Kritchevsky SB, Williamson JD, Pardee TS, Ellis LR, Powell BL. Geriatric assessment predicts survival for older adults receiving induction chemotherapy for acute myelogenous leukemia. Blood. 2013;121(21):4287-4294.

Marcucci G, Maharry KS, Metzeler KH, Volinia S, Wu YZ, Mrozek K, Nicolet D, Kohlschmidt J, Whitman SP, Mendler JH, Schwind S, Becker H, Eisfeld AK, Carroll AJ, Powell BL, Kolitz JE, Garzon R, Caligiuri MA, Stone RM, Bloomfield CD. Clinical role of microRNAs in cytogenetically normal acute myeloid leukemia: miR-155 upregulation independently identifies high-risk patients. J Clin Oncol. 2013;31(17):2086-2093.

Metzeler KH, Maharry K, Kohlschmidt J, Volinia S, Mrozek K, Becker H, Nicolet D, Whitman SP, Mendler JH, Schwind S, Eisfeld AK, Wu YZ, Powell BL, Carter TH, Wetzler M, Kolitz JE, Baer MR, Carroll AJ, Stone RM, Caligiuri MA, Marcucci G, Bloomfield CD. A stem cell-like gene expression signature associates with inferior outcomes and a distinct microRNA expression profile in adults with primary cytogenetically normal acute myeloid leukemia. Leukemia. 2013;27(10):2023-2031.


Marcucci G, Metzeler KH, Schwind S, Becker H, Maharry K, Mrozek K, Radmacher MD, Kohlschmidt J, Nicolet D, Whitman SP, Wu Y-Z, Powell BL, Carter TH, Kolitz JE, Wetzler M, Carroll AJ, Baer MR, Moore JO, Caligiuri MA,. Age-related prognostic impact of different types of DNMT3A mutations in adults with primary cytogenetically normal acute myeloid leukemia. J Clin Oncol. 2012;30(7):742-750.

Nicolini FE, Masszi T, Shen Z, Gallagher NJ, Jootar S, Powell BL, Dorlhiac-Llacer PE, Zheng M, Szczudlo T, Turkina A. Expanding Nilotinib Access in Clinical Trials (ENACT), an open-label multicenter study of oral nilotinib in adult patients with imatinib-resistant or -intolerant chronic myeloid leukemia in accelerated phase or blast crisis. Leuk Lymphoma. 2012;53(5):907-914.

Walter RB, Medeiros BC, Powell BL, Schiffer CA, Appelbaum FR, Estey EH. Phase II trial of vorinostat and gemtuzumab ozogamicin as induction and post-remission therapy in older adults with previously untreated acute myeloid leukemia. Haematologica. 2012;97(5):739-742.

High KP, Case D, Hurd D, Powell B, Lesser G, Falsey AR, Siegel R, Metzner-Sadurski J, Krauss JC, Chinnasami B, Sanders G, Rousey S, Shaw EG. A randomized, controlled trial of Panax quinquefolius extract (CVT-E002) to reduce respiratory infection in patients with chronic lymphocytic leukemia. J Support Oncol. 2012;10(5):195-201.

Whitman SP, Caligiuri MA, Maharry K, Radmacher MD, Kohlschmidt J, Becker H, Mrozek K, Wu YZ, Schwind S, Metzeler KH, Mendler JH, Wen J, Baer MR, Powell BL, Carter TH, Kolitz JE, Wetzler M, Carroll AJ, Larson RA, Marcucci G, Bloomfield CD. The MLL partial tandem duplication in adults aged 60 years and older with de novo cytogenetically normal acute myeloid leukemia [letter]. Leukemia. 2012;26(7):1713-1717.

Eisfeld A-K, Marcucci G, Maharry K, Schwind S, Radmacher MD, Nicolet D, Becker H, Mrozek K, Whitman SP, Metzeler KH, Mendler JH, Wu Y-Z, Liyanarachchi S, Patel R, Baer MR, Powell BL, Carter TH, Moore JO, Kolitz JE, Wetzler M, Caligiuri MA,. miR-3151 interplays with its host gene BAALC and independently affects outcome of patients with cytogenetically normal acute myeloid leukemia. Blood. 2012;120(2):249-258.

Mendler JH, Maharry K, Radmacher MD, Mrozek K, Becker H, Metzeler KH, Schwind S, Whitman SP, Khalife J, Kohlschmidt J, Nicolet D, Powell BL, Carter TH, Wetzler M, Moore JO, Kolitz JE, Baer MR, Carroll AJ, Larson RA, Caligiuri MA,. RUNX1 mutations are associated with poor outcome in younger and older patients with cytogenetically normal acute myeloid leukemia and with distinct gene and microRNA expression signatures. J Clin Oncol. 2012;30(25):3109-3118.

Kutny MA, Moser BK, Laumann K, Feusner JH, Gamis A, Gregory J, Larson RA, Powell BL, Stock W, Willman CL, Woods WG, Meshinchi S. FLT3 mutation status is a predictor of early death in pediatric acute promyelocytic leukemia: a report from the Children's Oncology Group. Pediatr Blood Cancer. 2012;59(4):662-667.

Gallagher RE, Moser BK, Racevskis J, Poire X, Bloomfield CD, Carroll AJ, Ketterling RP, Roulston D, Schachter-Tokarz E, Zhou DC, Chen IM, Harvey R, Koval G, Sher DA, Feusner JH, Tallman MS, Larson RA, Powell BL, Appelbaum FR,. Treatment-influenced associations of PML-RAR alpha mutations, FLT3 mutations, and additional chromosome abnormalities in relapsed acute promyelocytic leukemia. Blood. 2012;120(10):2098-2108.

Klepin HD, Powell BL. Management of myelodysplastic syndromes and acute leukaemia In: Sinclair AJ, Morley JE, Vellas B, eds. Pathy's principles and practice of geriatric medicine, vol 1. 5th ed. Oxford (UK): Wiley-Blackwell;2012: 375-385.

Blum W, Sanford B, Klisovic RB, DeAngelo DJ, Uy G, Powell BL, Stock W, Baer MR, Kolitz JE, Wegzler M, Hoke E, Bloomfield CD, Geyer S, Marcucci G, Stone RM, Larson RA. Maintenance therapy with decitabine in younger adults with acute myeloid leukemia (AML) in first remission: a phase II Cancer and Leukemia Group B Study (CALGB 10503, Alliance) [abstract]. Blood. 2012;120(21):Abstr 44.

Whitman S, Kohlschmidt J, Maharry K, Nicolet D, Schwind S, Becker H, Metzeler KH, Mrozek K, Mendler JH, Eisfeld A-K, Volinia S, Powell BL, Carter TH, Kolitz JE, Stone RM, Park I-K, Caligiuri MA, Marcucci G, Bloomfield CD. Adverse prognostic impact of GAS6 expression in de novo cytogenetically normal acute myeloid leukemia (CN-AML) (CALGB 8461, 9665, 20202; Alliance) [abstract]. Blood. 2012;120(21):1293.

Metzeler KH, Maharry K, Radmacher MD, Mrozek K, Margeson D, Becker H, Curfman J, Holland KB, Schwind S, Powell BL, et al. Mutations in the TET oncogene family member 2 (TET2) gene refine the new European leukemia net risk classification of primary, cytogeinetically normal acute myeloid leukemia in adults: a Cancer and Leukemia Group B Study [abstract]. Ann Hematol. 2011;90(Suppl 1):S8.

Metzeler KH, Maharry K, Radmacher MD, Mrozek K, Margeson D, Becker H, Curfman J, Holland KB, Schwind S, Powell BL, et al. TET2 mutations improve the new European LeukemiaNet risk classification of acute myeloid leukemia: a Cancer and leukemia Group B Study. J Clin Oncol. 2011;29(10):1373-1381.

Klepin HD, Danhauer SC, Tooze JA, Stott K, Daley K, Vishnevsky T, Powell BL, Mihalko SL. Exercise for older adult inpatients with acute myelogenous leukemia: a pilot study. J Geriatr Oncol. 2011;2(1):11-17.

Baer MR, George SL, Sanford BL, Mrozek K, Kolitz JE, Moore JO, Stone RM, Powell BL, Caligiuri MA, Bloomfield CD, et al. Escalation of daunorubicin and addition of etoposide in the ADE regimen in acute myeloid leukemia patients aged 60 years and older: Cancer and Leukemia Group B Study 9720. Leukemia. 2011;25(5):800-807.

Geller R, Tooze JA, Powell BL, Klepin H. The prevalence and prognostic significance of polypharmacy in older adults treated for acute myelogenous leukemia (AML) [abstract]. J Am Geriatr Soc. 2011;59(Suppl 1):S57.

Powell BL. Arsenic trioxide in acute promyelocytic leukemia: potion not poison [editorial]. Expert Rev Anticancer Ther. 2011;11(9):1317-1319.

Becker H, Maharry K, Radmacher MD, Mrozek K, Metzeler KH, Whitman SP, Schwind S, Kohlschmidt J, Wu Y-Z, Powell BL, et al. Clinical outcome and gene- and microRNA-expression profiling according to the Wilms tumor 1 (WT1) single nucleotide polymorphism rs16754 in adult de novo cytogenetically normal acute myeloid leukemia: a Cancer and Leukemia Group B study. Haematologica. 2011;96(10):1488-1495.

Klepin HD, Geiger AM, Tooze JA, Kritchevsky SB, Williamson JD, Ellis LR, Levitan D, Pardee TS, Isom S, Powell BL. The feasibility of inpatient geriatric assessment for older adults receiving induction chemotherapy for acute myelogenous leukemia. J Am Geriatr Soc. 2011;59(10):1837-1846.

Schwind S, Marcucci G, Kohlschmidt J, Radmacher MD, Mrozek K, Maharry K, Becker H, Metzeler KH, Whitman SP, Wu Y-Z, Powell BL, Baer MR, Kolitz JE, Carroll AJ, Larson RA, Caligiuri MA, Bloomfield CD. Low expression of MN1 associates with better treatment response in older patients with de novo cytogenetically normal acute myeloid leukemia. Blood. 2011;118(15):4188-4198.

Metzeler KH, Becker H, Maharry K, Radmacher MD, Kohlschmidt J, Mrozek K, Nicolet D, Whitman SP, Wu Y-Z, Schwind S, Powell BL, Carter TH, Wetzler M, Moore JO, Kolitz JE, Baer MR, Carroll AJ, Larson RA, Caligiuri MA, Marcucci G, Bloomfield CD. ASXL1 mutations identify a high-risk subgroup of older patients with primary cytogenetically normal AML within the ELN Favorable genetic category. Blood. 2011;118(26):6920-6929.

Eisfeld A-K, Marcucci G, Maharry K, Schwind S, Radmacher MD, Nicolet D, Becker H, Whitman SP, Metzeler KH, Mrozek K, Wu Y-Z, Baer MR, Powell BL, Carter TH, Moore JO, Kolitz JE, Wetzler M, Caligiuri MA, Larson RA, Tanner SM, et al. MiR-3151, a novel microRNA embedded in BAALC, is only weakly co-expressed with its host gene and independently impacts on the clinical outcome of older patients (Pts) with de novo cytogenetically normal acute myeloid leukemia (CN-AML) [abstract]. Blood. 2011;118(21):635.

Fenaux P, Giagounidis A, List AF, Nimer SD, Hellstrom-Lindberg E, Powell BL, Yu X, Skikne B, Shammo JM, del Canizo C. Outcomes for patients (Pts) with low-/Int-1-risk myelodysplastic syndromes (MDS) with del5q aged less than 65 years treated with lenalidomide (LEN) in MDS-003 and MDS-004: a retrospective combined analysis [abstract]. Blood. 2011;118(21):750-751.

Mendler JH, Maharry K, Radmacher MD, Mrozek K, Kohlschmidt J, Nicolet D, Becker H, Metzeler KH, Schwind S, Whitman SP, Blum W, Powell BL, Kolitz JE, Carter TH, Wetzler M, Moore JO, Carroll AJ, Baer MR, Larson RA,. Poor outcome of RUNX1-mutated (RUNX1-mut) patients (Pts) with primary, cytogenetically normal acute myeloid leukemia (CN-AML) and associated gene- and microRNA (miR) expression signatures [abstract]. Blood. 2011;118(21):1476-1477.

Metzeler KH, Becker H, Maharry K, Radmacher MD, Kohlschmidt J, Mrozek K, Nicolet D, Whitman SP, Wu Y-Z, Schwind S, Powell BL, Carter TH, Wetzler M, Moore JO, Kolitz JE, Baer MR, Carroll AJ, Larson RA, Caligiuri MA,. ASXL1 mutations identify a high-risk subgroup of older patients with primary cytogenetically normal acute myeloid leukemia within the European LeukemiaNet 'favorable' genetic category [abstract]. Blood. 2011;118(21):192.

Powell BL, Moser BK, Stock W, Gallagher RE, Willman CL, Stone RM, Rowe JM, Coutre SE, Feusner JH, Gregory J, Couban S, Appelbaum FR, Tallman MS, Larson RA. Adding mercaptopurine and methotrexate to alternate week ATRA maintenance therapy does not improve the outcome for adults with acute promyelocytic leukemia (APL) in first remission: results from North American Leukemia Intergroup Trial C9710 [abstract]. Blood. 2011;118(21):118-119.

Chiou V, Tiegs J, Isom S, Pettenati MJ, Lyerly S, Ellis LR, Pardee T, Dmitriy B, Powell BL, Levitan DA. A single institution analysis of incidence of recurrent chromosomal abnormalities in adult ALL patients according to race, gender, and age [abstract]. Blood. 2011;118(21):4869.

Becker H, Marcucci G, Maharry K, Radmacher MD, Mrozek K, Margeson D, Whitman SP, Wu Y-Z, Schwind S, Powell BL, et al. Favorable prognostic impact of NPM1 mutations in older patients with cytogenetically normal de novo acute myeloid leukemia and associated gene- and microRNA-expression signatures: a Cancer and Leukemia Group B Study. J Clin Oncol. 2010;28(4):596-604.

Marcucci G, Maharry K, Wu Y-Z, Radmacher MD, Mrozek K, Margeson D, Holland KB, Whitman SP, Becker H, Powell BL, et al. IDH1 and IDH2 gene mutations identify novel molecular subsets within de novo cytogenetically normal acute myeloid leukemia: a Cancer and Leukemia Group B study. J Clin Oncol. 2010;28(14):2348-2355.

Becker H, Marcucci G, Maharry K, Radmacher MD, Mrozek K, Margeson D, Whitman SP, Paschka P, Holland KB, Powell BL, et al. Mutations of the Wilms tumor 1 gene (WT1) in older patients with primary cytogenetically normal acute myeloid leukemia: a Cancer and Leukemia Group B study. Blood. 2010;116(5):788-792.

Becker H, Marcucci G, Maharry K, Radmacher M, Wu Y, Mrozek K, Whitman S, Margeson D, Holland K, Powell B, et al. CEBPA double mutations impact favorably on the outcome of older adults with wild-type Npm1 cytogenetically normal acute myeloid leukemia and are associated with distinct gene and microrna expression [abstract]. Haematologica. 2010;95(Suppl 2):247-248.

Marcucci G, Maharry K, Wu YZ, Radmacher M, Mrozek K, Margeson D, Holland K, Whitman S, Becker H, Powell B, et al. IDH1 and IDH2 gene mutations identify novel molecular subsets within de novo cytogenetically normal acute myeloid leukemia (CN-AML): a Cancer and Leukemia Group B (CALGB) Study [abstract]. Haematologica. 2010;95(Suppl 2):456.

Metzeler K, Maharry K, Margeson D, Curfman J, Becker H, Radmacher M, Mrozek K, Holland K, Whitman S, Powell B, et al. Tet2 mutations occur in over 20% of adults with de novo cytogenetically normal acute myeloid leukemia, and their prevalence increases with age: a Cancer and Leukemia Group B Study [abstract]. Haematologica. 2010;95(Suppl 2):12-13.

Walter B, Medeiros B, Nielsen-Stoeck M, Harrington E, Powell B, Schiffer C, Appelbaum F, Estey E. Phase 2 trial of vorinostat (SAHA) in combination with gemtuzumab ozogamicin as induction and post-remission therapy in older patients with previously untreated acute myeloid leukemia (AML) [abstract]. Haematologica. 2010;95(Suppl 2):29-30.

Kolitz JE, George SL, Marcucci G, Vij R, Powell BL, Allen SL, DeAngelo DJ, Shea TC, Stock W, Baer MR, et al. P-glycoprotein inhibition using valspodar (PSC-833) does not improve outcomes for patients younger than age 60 years with newly diagnosed acute myeloid leukemia: Cancer and Leukemia Group B study 19808. Blood. 2010;116(9):1413-1421.

Powell BL, Moser B, Stock W, Gallagher RE, Willman CL, Stone RM, Rowe JM, Coutre S, Feusner JH, Gregory J, et al. Arsenic trioxide improves event-free and overall survival for adults with acute promyelocytic leukemia: North American Leukemia Intergroup Study C9710. Blood. 2010;116(19):3751-3757.

Ranganathan A, Powell BL. Risk-adapted approaches to therapy for high-risk acute promyelocytic leukemia. Clin Lymphoma Myeloma Leuk. 2010;10(Suppl 3):S135-S138.

Schwind S, Maharry K, Radmacher MD, Mrozek K, Holland KB, Margeson D, Whitman SP, Hickey C, Becker H, Powell BL, et al. Prognostic significance of expression of a single microRNA, miR-181a, in cytogenetically normal acute myeloid leukemia: a Cancer and Leukemia Group B study. J Clin Oncol. 2010;28(36):5257-5264.

Tallman M, Douer D, Gore S, Powell BL, Ravandi F, Rowe J, Ranganathan A, Sanz MA. Treatment of patients with acute promyelocytic leukemia: a consensus statement on risk-adapted approaches to therapy. Clin Lymphoma Myeloma Leuk. 2010;10(Suppl 3):S122-S126.


Schwind S, Marcucci G, Maharry K, Radmacher MD, Mrozek K, Holland KB, Margeson D, Becker H, Whitman SP, Powell BL, et al. BAALC and ERG expression levels are associated with outcome and distinct gene and microRNA expression profiles in older patients with de novo cytogenetically normal acute myeloid leukemia: a Cancer and Leukemia Group B study. Blood. 2010;116(25):5660-5669.

Attar EC, Donohue KA, Amrein PC, Wadleigh M, DeAngelo DJ, Kolitz JE, Powell BL, Voorhees PM, Wang ES, Blum W, et al. Phase II study of bortezomib added to standard daunorubicin and cytarabine induction and dose escalation of bortezomib with intermediate-dose cytarabine consolidation therapy for patients with previously untreated acute myeloid leukemia age 60-75 years:. Blood. 2010;116(21):150.

Gallagher RE, Moser BK, Racevskis J, Poire X, Bloomfield CD, Carroll AJ, Ketterling R, Ralston D, Schachter-Tokarz E, Powell BL, et al. Clonal markers in relapsed acute promyelocytic leukemia (APL) clinicopathological associations and relation to all trans retinoic acid (ATRA) treatment on intergroup phase III Trial C9710 [abstract]. Blood. 2010;116(21):456.

Klepin HD, Tooze JA, Geiger AM, Kritchevsky S, Williamson J, Ellis LR, Levitan D, Pardee T, Isom S, Powell BL. Geriatric assessment predicts overall survival among older adults receiving induction chemotherapy for acute myelogenous leukemia [abstract]. Blood. 2010;116(21):653-654.

Metzeler KH, Maharry K, Radmacher MD, Mrozek K, Margeson D, Becker H, Curfman J, Holland KB, Schwind S, Powell BL, et al. Mutations in the TET oncogene family member 2 (TET2) gene refine the new European LeukemiaNet risk classification of primary, cytogenetically normal acute myeloid leukemia. Blood. 2010;116(21):48-49.

Rizzieri DA, Johnson JL, Byrd JC, Lozanski G, Powell BL, Shea TC, Nattom S, Hoke E, Cheson BD, Larson R. Efficacy and toxicity of rituximab and brief duration, high intensity chemotherapy with filgrastim support for Burkitt or Burkitt-like leukemia/lymphoma: Cancer and Leukemia Group B (CALGB) Study 10002 [abstract]. Blood. 2010;116(21):374-375.

Blum W, Donohue K, Marcucci G, DeAngelo DJ, Uy GL, Powell BL, Stock W, Baer M, Kolitz JE, Wetzler M, et al. Challenges for conducting clinical trials evaluating maintenance chemotherapy in acute myeloid leukemia (AML): a Cancer and Leukemia Group B (CALGB) study [abstract]. Blood. 2010;116(21):898-899.

Sekeres MA, Roboz GJ, Odenike O, Agura E, Powell BL, Ewesuedo R, Vasconcelles MJ, Faderl S, Kantarjian H. Preliminary results of fixed-dose oral clofarabine (CLO) in patients who have failed hypomethylating agents for the treatment of myelodysplastic syndromes (MDS) [abstract]. Blood. 2010;116(21):779.

Klepin HD, Powell BL. Management of myelodysplasia in older adults In: Hurria A, Cohen HJ, eds. Practical geriatric oncology. New York: Cambridge University Press;2010: 221-229.

Grinblatt DL, Yu D, Hars V, Vardiman JW, Powell BL, Nattam S, Silverman LR, de Castro C III, Stone RM, Bloomfield CD, et al. Treatment of myelodysplastic syndrome with 2 schedules and doses of oral topotecan: a randomized phase 2 trial by the Cancer and Leukemia Group B (CALGB 19803). Cancer. 2009;115(1):84-93.

Klepin HD, Powell BL. White cell disorders In: Halter JB, Ouslander JG, Tinetti ME, Studenski S, High KP, Asthana S, Hazzard WR, Wollard NF, eds. Hazzard's geriatric medicine and gerontology. 6th ed. New York: McGraw Hill Medical;2009: 1215-1227.

Klepin HD, Ellis LR, Levitan D, Powell BL. Feasibility of inpatient geriatric assessment for older adults with acute myelogenous leukemia [abstract]. J Am Geriatr Soc. 2009;57(Suppl 1):S155.

Langer C, Marcucci G, Holland KB, Radmacher MD, Maharry K, Paschka P, Whitman SP, Mrozek K, Baldus CD, Powell BL, et al. Prognostic importance of MN1 transcript levels, and biologic insights from MN1-associated gene and microRNA expression signatures in cytogenetically normal acute myeloid leukemia: a cancer and leukemia group B study. J Clin Oncol. 2009;27(19):3198-3204.

Cortes JE, Kantarjian HM, Goldberg SL, Powell BL, Giles FJ, Wetzler M, Akard L, Burke JM, Kerr R, Saleh M, et al. High-dose imatinib in newly diagnosed chronic-phase chronic myeloid leukemia: high rates of rapid cytogenetic and molecular responses. J Clin Oncol. 2009;27(28):4754-4759.

Linker CA, Owzar K, Powell B, Hurd D, Damon LE, Archer LE, Larson RA. Auto-SCT for AML in second remission: CALGB Study 9620. Bone Marrow Transplant. 2009;44(6):353-359.

Attar EC, Maharry K, Mrozek K, Radmacher MD, Whitman SP, Paschka P, Langer C, Holland KB, Powell BL, Kolitz JE, et al. Increased expression of macrophage migration inhibitory factor (MIF) receptor CD74 is associated with inferior outcome in younger patients (Pts) with cytogenetically normal acute myeloid leukemia (CN-AML):. Blood. 2009;114(22):645-646.

Erba HP, O'Donnell M, Allen SL, Baer MR, Powell BL, Stone RM, Bennett JM, Lundberg AS, Capizzi RL, Rizzieri DA. Amonafide L-malate (AS1413) in combination with cytarabine is equally effective in older and younger patients with secondary acute myeloid leukemia (AML); final data from a phase II study [abstract]. Blood. 2009;114(22):433-434.

Klepin HD, Geiger AM, Williamson J, Kritchevsky S, Tooze JA, Ellis LR, Levitan D, Isom S, Powell BL. Inpatient geriatric assessment detects impairment among older adults receiving induction chemotherapy for acute myelogenous leukemia [abstract]. Blood. 2009;114(22):570-571.

Powell BL, Khoury HJ, Lipton JH, Rizzieri DA, Williams D, Turner AR. Nilotinib responses and tolerability confirmed in North American patients with chronic myeloid leukemia (CML) from ENACT (Expanding Nilotinib Access in Clinical Trials) [abstract]. Blood. 2009;114(22):1277.

Schwind S, Marcucci G, Maharry K, Mrozek K, Radmacher MD, Holland KB, Becker H, Whitman SP, Wu Y-Z, Powell BL, et al. Aberrant gene expression of BAALC and ERG in older [>= 60 Years (y)] de novo cytogenetically normal acute myeloid leukemia (CN-AML): a Cancer and Leukemia Group B (CALGB) Study [abstract]. Blood. 2009;114(22):93-94.

Stock W, Sanford B, Lozanski G, Vij R, Byrd JC, Powell BL, Wetzler M, Sher D, Edwards C, Kelly M, et al. Alemtuzumab can be incorporated into front-line therapy of adult acute lymphoblastic leukemia (ALL): final phase I results of a Cancer and Leukemia Group B Study (CALGB 10102) [abstract]. Blood. 2009;114(22):345.

Whitman SP, Maharry K, Radmacher MD, Mrozek K, Margeson D, Holland KB, Becker H, Wu Y-Z, Schwind S, Powell BL, et al. Adverse prognostic impact of FLT3 internal tandem duplication (ITD) is age-associated in older [>= 60 Years (Y)] de novo cytogenetically normal acute myeloid leukemia (CN-AML) patients (Pts):. Blood. 2009;114(22):631-632.

Whitman SP, Ruppert AS, Radmacher MD, Mrozek K, Paschka P, Langer C, Baldus CD, Wen J, RAcke F, Powell BL, et al. FLT3 D835/I836 mutations are associated with poor disease-free survival and a distinct gene-expression signature among younger adults with de novo cytogenetically normal acute myeloid leukemia lacking FLT3 internal tandem duplications. Blood. 2008;111(3):1552-1559.

Levy M, Wofford MM, Powell BL, McLean TW. Hyperleukocytosis from arsenic trioxide. Pediatr Blood Cancer. 2008;50(6):1265-1267.

Marcucci G, Radmacher MD, Maharry K, Mrozek K, Ruppert AS, Paschka P, Vukosavljevic T, Whitman SP, Baldus CD, Powell BL, et al. MicroRNA expression in cytogenetically normal acute myeloid leukemia. N Engl J Med. 2008;358(18):1919-1928.

Langer C, Radmacher MD, Ruppert AS, Whitman SP, Paschka P, Mrozek K, Baldus CD, Vukosavljevic T, Liu C-G, Powell BL, et al. High BAALC expression associates with other molecular prognostic markers, poor outcome, and a distinct gene-expression signature in cytogenetically normal patients younger than 60 years. Blood. 2008;111(11):5371-5379.

Marcucci G, Maharry K, Radmacher MD, Mrozek K, Vukosavljevic T, Paschka P, Whitman SP, Langer C, Baldus CD, Powell BL, et al. Prognostic significance of, and gene and microRNA expression signatures associated with, CEBPA mutations in cytogenetically normal acute myeloid leukemia with high-risk molecular features: a Cancer and Leukemia Group B Study. J Clin Oncol. 2008;26(31):5078-5087.

Paschka P, Marcucci G, Ruppert AS, Whitman SP, Mrozek K, Maharry K, Langer C, Baldus CD, Zhao W, Powell BL, et al. Wilms' tumor 1 gene mutations independently predict poor outcome in adults with cytogenetically normal acute myeloid leukemia: a Cancer and Leukemia Group B study. J Clin Oncol. 2008;26(28):4595-4602.

Powell B, D'Agostino R Jr, Levitan D, Ellis LR, Lyerly S, Skiles M, Manuel M, Harrelson R, Kimbrough C, Hurd DD. High dose cytarabine and clofarabine (HiDAC-->CLOF) in relapsed or refractory acute myeloid leukemia, a phase 2 trial [abstract]. Blood. 2008;112(11):676.

Allen SL, Erba HP, Rizzieri DA, O'Donnell M, Powell B, Lundberg AS, Bennett JM, Capizzi RL. Secondary acute myeloid leukemia (sAML) treated with amonafide (AS1413) + cytarabine: durable responses in poor-risk AML [abstract]. Blood. 2008;112(11):1019-1020.

Nicolini F, Alimena G, Shen Z, Al-Ali HK, Turkina A, Smith G, Pasquini R, Jootar S, Hsu Y, Powell B, et al. Expanding Nilotinib Access in Clinical Trials (ENACT) Study in adult patients with imatinib-resistant or intolerant chronic myeloid leukemia (CML): updated safety analysis [abstract]. Haematologica. 2008;93(Suppl 1):53.

Baer MR, George SL, Caligiuri MA, Sanford BL, Bothun SM, Mrozek K, Kolitz JE, Powell BL, Moore JO, Stone RM, et al. Low-dose interleukin-2 immunotherapy does not improve outcome of patients age 60 years and older with acute myeloid leukemia in first complete remission: Cancer and Leukemia Group B Study 9720. J Clin Oncol. 2008;26(30):4934-4939.

Molnar I, Stark N, Lovato J, Powell BL, Cruz J, Hurd DD, Mathieu JS, Cambra S, McQuellon RP, Schwartz GG, et al. Treatment of low-risk myelodysplastic syndromes with high-dose daily oral cholecalciferol (2000-4000 IU vitamin D(3)) [letter]. Leukemia. 2007;21(5):1089-1092.

Molnar I, Powell BL. What role does gemtuzumab ozogamicin have in the treatment of acute myelogenous leukemia?. Curr Hematol Malig Rep. 2007;2(2):104-110.

Powell BL, Moser B, Stock W, Gallagher RE, Willman C, Coutre W, Feusner JH, Appelbaum FR, Tallman MS, Larson RA. Effect of consolidation with arsenic trioxide (As2O3) on event-free survival (EFS) and overall survival (OS) among patients with newly diagnosed acute promyelocytic leukemia (APL): North American Intergroup Protocol C9710 [abstract]. J Clin Oncol. 2007;25(18 Suppl Pt I):Abstr 2.

Stock W, Moser B, Powell BL, Appelbaum FR, Tallman MS, Larson RA, Feusner JH, Bloomfield CD, Willman C, Gallagher RE. Prognostic significance of initial clinical and molecular genetic features of acute promyelocytic leukemia (APL): results from the North American Intergroup Trial, C9710 [abstract]. J Clin Oncol. 2007;25(18 Suppl Pt I):Abstr 7016.

Wetzler M, Sanford BL, Kurtzberg J, DeOliverira D, Frankel SR, Powell BL, Kolitz JE, Bloomfield CD, Larson RA. Effective asparagine depletion with pegylated asparaginase results in improved outcomes in adult acute lymphoblastic leukemia: Cancer and Leukemia Group B Study 9511. Blood. 2007;109(10):4164-4167.

Marcucci G, Maharry K, Whitman SP, Vukosavljevic T, Paschka P, Langer C, Mrozek K, Baldus CD, Carroll AJ, Powell BL, et al. High expression levels of the ETS-related gene, ERG, predict adverse outcome and improve molecular risk-based classification of cytogenetically normal acute myeloid leukemia: a Cancer and Leukemia Group B Study. J Clin Oncol. 2007;25(22):3337-3343.

Whitman SP, Ruppert AS, Marcucci G, Mrozek K, Paschka P, Langer C, Baldus CD, Wen J, Vukosavljevic T, Powell BL, et al. Long-term disease-free survivors with cytogenetically normal acute myeloid leukemia and MLL partial tandem duplication: a Cancer and Leukemia Group B study. Blood. 2007;109(12):5164-5167.

Paschka P, Marcucci G, Maharry K, Whitman SP, Ruppert AS, Vukosavljevic T, Mrozek K, Powell BL, Kolitz JE, Larson RA, et al. Prognostic impact of NPM1 mutations in cytogenetically normal (CN) acute myeloid leukemia (AML) is adversely affected by high expression of the ERG gene: a Cancer and Leukemia Group B (CALGB) study [abstract]. Haematologica. 2007;92(Suppl 1):145.

List A, Dewald G, Bennett J, Giagounidis A, Raza A, Feldman E, Powell B, Greenberg P, Thomas D, Stone R, et al. Lenalidomide in the myelodysplastic syndrome with chromosome 5q deletion. N Engl J Med. 2006;355(14):1456-1465.

Powell BL, Lovato J, Kimbrough C, Lyerly S, Galloway-Daniels S, Harrelson R, Keung YK, Thakuri MC, Molnar I, Levitan D, Hurd DD, et al. Limited phase I trial of sequential high dose cytarabine and clofarabine (HiDAC-->CLOF) in relasped or refractory acute myeloid leukemia [abstract]. Blood. 2006;108(11 Pt 2):221b.

Silverman LR, Peterson BL, Holland JF, Stone RM, Powell BL, Larson RA. Transfusion independence in patients with myelodysplastic syndromes treated with azacitidine [abstract]. J Clin Oncol. 2006;24(18 Suppl Pt I):355s.

Druker BJ, Guilhot F, O'Brien SG, Gathmann I, Kantarjian H, Gattermann N, Deininger MWN, Silver RT, Goldman JM, Powell BL, et al. Five-year follow-up of patients receiving imatinib for chronic myeloid leukemia. N Engl J Med. 2006;355(23):2408-2417.

Cortes J, Giles F, Salvado AJ, McDougall K, Radich J, Albitar M, Powell BL, Goldberg S, Kantarjian HM. Molecular responses in newly diagnosed chronic myelocytic leukemia (CML) patients treated with 800 mg imatinib daily: an update from the RIGHT trial study group [abstract]. Blood. 2006;108(11 Pt 1):609a-610a.

DeAngelo DJ, Amrein PC, Kovacsovics TJ, Klisovic RB, Powell BL, Cooper M, Webb IJ, Stone RM. Phase 1/2 study of tandutinib (MLN518) plus standard induction chemotherapy in newly diagnosed acute myelogenous leukemia (AML) [abstract]. Blood. 2006;108(11 Pt 1):51a.

List AF, Dewald GW, Bennett JM, Giagounidis A, Raza A, Feldman EJ, Powell BL, Greenberg PL, Nimer SD, Zeldis JB, et al. Long-term clinical benefit of lenalidomide (Revlimid) treatment in patients with myelodysplastic syndrome and chromosome deletion 5q [abstract]. Blood. 2006;108(11 Pt 1):78a.

List AF, Esposito J, Decker J, Baer MR, Powell B, Steensma D, Raza A, Terebelo H, Maciejewski J, Goldberg SL, et al. Iron parameters in 84 MDS patients enrolled in a deferasirox (Exjade ICL670) multicenter trial [abstract]. Blood. 2006;108(11 Pt 2):297b.

Baer MR, George SL, Caligiuri MA, Sanford BL, O'Loughlin KL, Mrozek K, Kolitz JE, Powell BL, Moore JO, Stone RM, et al. Phase III study of immunotherapy with recombinant interleukin-2 (IL-2) versus no further therapy in acute myeloid leukemia (AML) patients greater than or equal to 60 years in first complete remission (CALGB 9720) [abstract]. Blood. 2006;108(11):Abstr 424.

Gallagher RE, Schachter-Tokarz EL, Moser BK, Sher D, Paietta E, Tallman MS, Bloomfield CD, Powell BL, Larson RA, Appelbaum FR, et al. Frequent PML-RAR alpha mutations in relapse patients on acute promyelocytic leukemia (APL) intergroup phase III trial C9710 [abstract]. Blood. 2006;108():Abstr 2342.

Powell BL, Moser B, Stock W, Gallagher RE, Willman CL, Stone RM, Rowe JM, Coutre S, Feusner JH, Gregory J, et al. Preliminary results from the North American Acute Promyelocytic Leukemia (APL) Study C9710 [abstract]. Blood. 2006;108(11):Abstr 566.

Stock W, Moser B, Sher DA, Schachter-Tokarz E, Myers M, Powell BL, Bloomfield CD, Bucci D, Tallman MS, Larson RA, et al. PML-RARalpha isoform at diagnosis is associated with disease-free survival (DFS) in patients enrolled in the intergroup trial (C-9710) for treatment of acute promyelocytic leukemia (APL) [abstract]. J Clin Oncol. 2006;24(18 Suppl Pt I):Abstr 6504.

Stock W, Harvey R, Moser B, Sher D, Schachter-Tokarz E, Myers M, Slack J, Powell B, Bloomfield CD, Larson RA, et al. Minimal residual disease (MRD) and risk of relapse in acute promyelocytic leukemia (APL): insights from the North American Intergroup Phase III Trial C9710 [abstract]. Blood. 2006;108(11):Abstr 494.

All Publications

For a listing of recent publications, refer to PubMed, a service provided by the National Library of Medicine.

For a list of earlier publications, visit the Carpenter Library Publication Search.

Professor, Hematology & Oncology

Clinical Interests

Acute Leukemias, Chronic Leukemias, Myelodysplastic Syndromes, Acute and Chronic Leukemia, Hematologic Malignancies, Leukemia
Bayard L. Powell, M.D.

Bayard L. Powell, M.D.

Director-At-Large, Comprehensive Cancer Center
Section Chief, Hematology & Oncology
Professor, Hematology & Oncology
Comprehensive Cancer Center

Doctor Rating

4.8 out of 5

Bayard L. Powell, M.D.162 Ratings
1 Comments

Doctor Ratings

The overall Patient Rating score is the average of responses to the nine questions listed below. The questions are from the Press Ganey Patient Satisfaction Survey. Responses are measured on a 1 to 5 scale, where 1 represents "very poor" and 5 represents "very good."
Press Ganey Patient Satisfaction Survey

CP concern for questions/worries
4.9
CP efforts to include in decisions
4.9
CP explanations of prob/condition
4.9
CP spoke using clear language
4.9
Friendliness/courtesy of CP
4.9
Likelihood of recommending CP
4.9
Patients' confidence in CP
4.9
Time CP spent with patient
4.8
Wait time at clinic
4.4



Patient Comments

Comments are taken from the Care Provider section of the Press Ganey Patient Satisfaction Survey. Comments are posted exactly as they are written. Comments are added weekly. To protect patient privacy and confidentiality, patient names are not included.

8/29/2014

Very good I have been in remission for 15 yrs.

Quick Reference

Request an Appointment
New Patients

336-716-WAKE
888-716-WAKE

Existing patients may contact the clinic directly.
Find a Doctor Ways to Give
USNWR 2013-2014Magnet Hospital RecognitionConsumer Choice2014 Best DoctorsJoint Commission Report

Disclaimer: The information on this website is for general informational purposes only and SHOULD NOT be relied upon as a substitute for sound professional medical advice, evaluation or care from your physician or other qualified health care provider.